Dynamic inflammatory biomarkers as prognostic indicators in advanced breast cancer patients receiving PD-1 inhibitors
Therapeutic Advances in Medical Oncology · 2026-05 · 18
DOI: 10.1177/17588359261443939 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 13.05.2026. Verfasst von Na Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, Medical Research Fund in Guangdong Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
While programmed cell death protein 1 (PD-1) inhibitors benefit breast cancer patients, simple predictors of their efficacy are lacking.
Objectives
This study aimed to evaluate inflammatory markers as prognostic indicators for advanced breast cancer (ABC) patients receiving immunotherapy.
Design
This is a single-center retrospective study of ABC patients treated with PD-1 inhibitors between January 2016 and June 2022.
Methods
Clinicopathological parameters, tumor-infiltrating lymphocytes (TILs) levels, and inflammatory markers—C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-monocyte ratio (LMR)—were collected from 116 ABC patients at baseline and after three cycles of immunotherapy (CRP3, NLR3, LMR3). Optimal cut-offs were defined using R software and associations with progression-free survival (PFS), overall survival (OS), and objective response rate were assessed.
Results
Low baseline CRP, low NLR, and high LMR were significantly associated with improved PFS and OS (all p < 0.05) by Kaplan–Meier analysis. On multivariate analysis, low NLR3 and a reduced CRP3/CRP ratio independently predicted prolonged PFS ( p < 0.05). Patients with low CRP, reduced CRP3/CRP ratio, low NLR, and low NLR3 achieved better OS ( p < 0.05). Combining inflammatory markers with TIL status improved prognostic classification: TIL-deficient patients with high NLR3 (median PFS (mPFS): 2.89 months) or high CRP3/CRP ratio (mPFS: 1.90 months) had the poorest survival ( p < 0.05).
Conclusion
CRP and NLR are promising biomarkers for predicting outcomes of PD-1 inhibitor therapy in ABC, with potential utility in individualizing immunotherapy strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 651 Dong Feng Road East, Guangzhou, Guangd…
ORCID-Profile: Na Wang, Shusen Wang, Fei Xu, Kuikui Jiang
Förderung
- Beijing Xisike Clinical Oncology Research Foundation
- Medical Research Fund in Guangdong Province
Zitieren
APA
Wang, N., Yi, P., Lu, Q., Zhong, Y., Xue, C., Zhang, P., Wang, S., Yuan, Z., Shi, Y., Chen, H., Xu, F., & Jiang, K. (2026). Dynamic inflammatory biomarkers as prognostic indicators in advanced breast cancer patients receiving PD-1 inhibitors. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261443939
Vancouver
Wang N, Yi P, Lu Q, Zhong Y, Xue C, Zhang P, et al. Dynamic inflammatory biomarkers as prognostic indicators in advanced breast cancer patients receiving PD-1 inhibitors. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261443939
BibTeX
@article{Wang2026,
author = {Wang, Na and Yi, Peijun and Lu, Qianyi and Zhong, Yi and Xue, Cong and Zhang, Ping and Wang, Shusen and Yuan, Zhongyu and Shi, Yanxia and Chen, Hanmu and Xu, Fei and Jiang, Kuikui},
title = {Dynamic inflammatory biomarkers as prognostic indicators in advanced breast cancer patients receiving PD-1 inhibitors},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261443939}
}
EUVIMED